Celadon Pharmaceuticals PLC Appointment of CFO (8069E)

TIDMCEL

RNS Number : 8069E

Celadon Pharmaceuticals PLC

01 November 2022

Celadon Pharmaceuticals Plc

("Celadon", the "Company" or the "Group")

Appointment of CFO

London, 1 November 2022 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines, today announces the appointment of Jonathan Turner as Chief Financial Officer of the Group. Jonathan will start a phased transition into his role from November 2022 and will join the Company on a full time basis from February 2023. He will be appointed to the Board at that time.

Jonathan succeeds Katie Long who is returning to her role within Tessera Investment Management Limited ("Tessera"), having established and led Celadon's finance function over the previous year and during the Company's AIM IPO. Katie will continue to provide support to the Company through to the commencement of Jonathan's appointment on a full time basis, and will step down from the Board at that time.

Jonathan joins from FTSE250 listed Oxford Instruments plc (LSE: OXIG), where he has been Group Director of Accounting, Tax and Treasury since September 2020, and a Divisional Finance Director for the three years before that. During this time, he has worked closely with the Oxford Instruments plc's CFO and has been responsible for internal and external financial reporting, and developing and maintaining financial and operational systems.

Prior to this, Jonathan was Group Company Secretary and Head of Tax and Treasury for FTSE listed Synergy Health plc ("Synergy") and Finance Director for NYSE listed STERIS plc, following its acquisition of Synergy. Jonathan is a Chartered Accountant and Associate Member of the Association of Corporate Treasurers and was previously a Senior Manager at EY, where he worked from 2003 until 2010, and originally qualified at Smith & Williamson.

James Short, CEO of Celadon, said:

"We are delighted to welcome Jonathan to the Group. His extensive experience operating within technology, manufacturing and scientific research industries will be important as Celadon continues to advance its position as a leading UK provider of breakthrough cannabis-based medicines.

"The Board would like to take this opportunity to thank Katie for her invaluable contribution since joining Celadon in February 2021, which has been a pivotal time in the Company's development. We wish her well on her return to Tessera."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Jonathan Paul Turner, aged 44 years, has been a director of the following companies during the five years preceding the date of this announcement:

 
 Current directorships                Past Directorships 
 Oxford Instruments Overseas          Oxford Instruments Nanotechnology 
  Holdings 2008 (since August          Tools Limited (April 2018 
  2020)                                - August 2020) 
  Oxford Instruments Nanotechnology    Oxford Instruments Industrial 
  Tools Holdings Limited               Products Limited (April 
  (since August 2020)                  2018 - July 2020) 
  Oxford Instruments Industrial 
  Products Holdings Limited 
  (since August 2020) 
  Oxford Instruments AFM 
  Limited (since August 
  2020) 
  Oxford Instruments Molecular 
  Biotools Limited (since 
  August 2020) 
  Oxford Instruments UK 
  2013 Limited (since August 
  2020) 
  Oxford Instruments Holdings 
  Europe Limited (August 
  2020) 
  Oxford Instruments Overseas 
  Holdings Limited (since 
  August 2020) 
  Oxford Instruments Funding 
  Limited (since August 
  2020) 
 

Mr Turner is expected to resign from the above directorships ahead of his formal appointment as a director of the Company.

Mr Turner was Director of, and Company Secretary to Shiloh Properties Limited between July 2014 and December 2016. The Company was dissolved via a Compulsory Strike Off in January 2022 following a restoration by court order from a previous voluntary wind-up of the Company. Mr Turner is not aware of any shortfall to creditors.

The Company confirms that there is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

Enquiries:

 
 Celadon Pharmaceuticals Plc 
 James Short                                    Via Powerscourt 
  Arthur Wakeley 
 
 Canaccord Genuity Limited (Nominated 
  Adviser and Broker) 
 Bobbie Hilliam / Andrew Potts / Patrick 
  Dolaghan                                      [phone] 
 
 Powerscourt Group 
 Sarah MacLeod / Nick Johnson / Sam Austrums    [phone] 
  /                                              [e-mail] 
  Ibrahim Khalil 
 

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility comprises a laboratory designed to meet GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office Licence to legally grow high-THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally-approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK.

For further information please visit our website www.celadonpharma.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFZMFGNMRGZZM

(END) Dow Jones Newswires

November 01, 2022 03:00 ET (07:00 GMT)